首页 > 最新文献

Lung Cancer Management最新文献

英文 中文
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. 晚期非小细胞肺癌患者BMI与免疫检查点抑制剂应答的相关性研究
IF 2.8 Q4 RESPIRATORY SYSTEM Pub Date : 2020-02-25 DOI: 10.2217/lmt-2019-0016
Alain Gelibter, Mario Occhipinti, Simona Pisegna, Alessio Cortellini, Enrico Cortesi, Paolo Marchetti
Alain Gelibter*,1, Mario Occhipinti1 , Simona Pisegna1, Alessio Cortellini2,3, Enrico Cortesi1 & Paolo Marchetti1,4 1Medical Oncology Unit, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy 2Medical Oncology Unit, St. Salvatore Hospital, L’Aquila, Italy 3Department of Biotechnological & Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 4U.O.C. Oncologia Medica, Azienda Ospedaliero Universitaria Sant’Andrea, Rome, Italy *Author for correspondence: alain.gelibter@uniroma1.it
{"title":"Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer.","authors":"Alain Gelibter, Mario Occhipinti, Simona Pisegna, Alessio Cortellini, Enrico Cortesi, Paolo Marchetti","doi":"10.2217/lmt-2019-0016","DOIUrl":"https://doi.org/10.2217/lmt-2019-0016","url":null,"abstract":"Alain Gelibter*,1, Mario Occhipinti1 , Simona Pisegna1, Alessio Cortellini2,3, Enrico Cortesi1 & Paolo Marchetti1,4 1Medical Oncology Unit, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy 2Medical Oncology Unit, St. Salvatore Hospital, L’Aquila, Italy 3Department of Biotechnological & Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 4U.O.C. Oncologia Medica, Azienda Ospedaliero Universitaria Sant’Andrea, Rome, Italy *Author for correspondence: alain.gelibter@uniroma1.it","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 2","pages":"LMT26"},"PeriodicalIF":2.8,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37882475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer. 早期肺癌术后液体活检分子残留检测优化
IF 2.8 Q4 RESPIRATORY SYSTEM Pub Date : 2020-02-21 DOI: 10.2217/lmt-2019-0017
Anna L McGuire, Curtis B Hughesman, Melissa K McConechy, Barb Melosky, Stephen Lam, Renelle Myers, John Yee, Ernest Tang, Stephen Yip
Anna L McGuire*,1, Curtis B Hughesman2, Melissa K McConechy3, Barb Melosky4,5, Stephen Lam4,6, Renelle Myers4,6, John Yee1, Ernest Tang1 & Stephen Yip2,7 1Department of Surgery, Division of Thoracic Surgery, Vancouver General Hospital, University of British Columbia, Vancouver V5Z1M9, BC, Canada 2Department of Pathology and Laboratory Medicine, BC Cancer, Cancer Genetics & Genomics Laboratory, Vancouver, BC, Canada 3Contextual Genomics Inc., Vancouver, BC, Canada 4Department of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Vancouver, BC, Canada 5Medical Oncology, University of British Columbia, Vancouver, BC, Canada 6Department of Medicine, Divisions of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada 7Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada *Author for correspondence: anna.mcguire@vch.ca
{"title":"Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer.","authors":"Anna L McGuire, Curtis B Hughesman, Melissa K McConechy, Barb Melosky, Stephen Lam, Renelle Myers, John Yee, Ernest Tang, Stephen Yip","doi":"10.2217/lmt-2019-0017","DOIUrl":"https://doi.org/10.2217/lmt-2019-0017","url":null,"abstract":"Anna L McGuire*,1, Curtis B Hughesman2, Melissa K McConechy3, Barb Melosky4,5, Stephen Lam4,6, Renelle Myers4,6, John Yee1, Ernest Tang1 & Stephen Yip2,7 1Department of Surgery, Division of Thoracic Surgery, Vancouver General Hospital, University of British Columbia, Vancouver V5Z1M9, BC, Canada 2Department of Pathology and Laboratory Medicine, BC Cancer, Cancer Genetics & Genomics Laboratory, Vancouver, BC, Canada 3Contextual Genomics Inc., Vancouver, BC, Canada 4Department of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Vancouver, BC, Canada 5Medical Oncology, University of British Columbia, Vancouver, BC, Canada 6Department of Medicine, Divisions of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada 7Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada *Author for correspondence: anna.mcguire@vch.ca","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 2","pages":"LMT24"},"PeriodicalIF":2.8,"publicationDate":"2020-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37882474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach? 化疗和/或免疫检查点抑制剂在非小细胞肺癌一线:什么是最好的方法?
IF 2.8 Q4 RESPIRATORY SYSTEM Pub Date : 2020-02-12 DOI: 10.2217/lmt-2019-0018
Luigi Della Gravara, Ciro Battiloro, Rosa Cantile, Antonietta Letizia, Fabiana Vitiello, Vincenzo Montesarchio, Danilo Rocco
Luigi Della Gravara1, Ciro Battiloro2, Rosa Cantile2, Antonietta Letizia2, Fabiana Vitiello2, Vincenzo Montesarchio3 & Danilo Rocco*,2 1Department of Experimental Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Caserta, Italy 2Division of Pulmonary Oncology, AORN dei Colli Monaldi, Naples, Italy 3Division of Medical Oncology, AORN dei Colli Monaldi, Naples, Italy *Author for correspondence: danilorocc@yahoo.it
{"title":"Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?","authors":"Luigi Della Gravara, Ciro Battiloro, Rosa Cantile, Antonietta Letizia, Fabiana Vitiello, Vincenzo Montesarchio, Danilo Rocco","doi":"10.2217/lmt-2019-0018","DOIUrl":"https://doi.org/10.2217/lmt-2019-0018","url":null,"abstract":"Luigi Della Gravara1, Ciro Battiloro2, Rosa Cantile2, Antonietta Letizia2, Fabiana Vitiello2, Vincenzo Montesarchio3 & Danilo Rocco*,2 1Department of Experimental Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Caserta, Italy 2Division of Pulmonary Oncology, AORN dei Colli Monaldi, Naples, Italy 3Division of Medical Oncology, AORN dei Colli Monaldi, Naples, Italy *Author for correspondence: danilorocc@yahoo.it","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 1","pages":"LMT22"},"PeriodicalIF":2.8,"publicationDate":"2020-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation. 化疗后接受检查点抑制剂的III期非小细胞肺癌患者的实际挑战。
IF 2.8 Q4 RESPIRATORY SYSTEM Pub Date : 2020-02-06 DOI: 10.2217/lmt-2020-0001
Nikhil A Shukla, Nasser H Hanna
NSCLC accounts for 80% of all lung cancer diagnoses, and approximately a third of patients present with locally advanced (stage III) disease [1]. The optimal therapy for fit patients with unresectable and/or inoperable stage III disease has evolved over the last three decades from radiation alone to sequential chemoradiation (CRT) to concurrent CRT followed by checkpoint inhibitor therapy (CPI). The recently reported PACIFIC trial generated a paradigm shift in the treatment of such patients, with a 3-year overall survival (OS) of 57% for patients receiving consolidation durvalumab compared with 43.5% for those receiving placebo [2–4]. Similar outcomes were reported with consolidation pembrolizumab in a Hoosier Cancer Research Network (HCRN) Phase II Trial [5]. In this article, we explore key clinical challenges that arise when treating patients with consolidation CPI after CRT for patients with stage III NSCLC; namely, the management of CPI-related pneumonitis, timing of consolidation CPI and their role in patients with PD-L1 TPS <1% and distinguishing local progression versus pseudoprogression.
{"title":"Practical challenges in patients with stage III NSCLC receiving checkpoint inhibitors after chemoradiation.","authors":"Nikhil A Shukla,&nbsp;Nasser H Hanna","doi":"10.2217/lmt-2020-0001","DOIUrl":"https://doi.org/10.2217/lmt-2020-0001","url":null,"abstract":"NSCLC accounts for 80% of all lung cancer diagnoses, and approximately a third of patients present with locally advanced (stage III) disease [1]. The optimal therapy for fit patients with unresectable and/or inoperable stage III disease has evolved over the last three decades from radiation alone to sequential chemoradiation (CRT) to concurrent CRT followed by checkpoint inhibitor therapy (CPI). The recently reported PACIFIC trial generated a paradigm shift in the treatment of such patients, with a 3-year overall survival (OS) of 57% for patients receiving consolidation durvalumab compared with 43.5% for those receiving placebo [2–4]. Similar outcomes were reported with consolidation pembrolizumab in a Hoosier Cancer Research Network (HCRN) Phase II Trial [5]. In this article, we explore key clinical challenges that arise when treating patients with consolidation CPI after CRT for patients with stage III NSCLC; namely, the management of CPI-related pneumonitis, timing of consolidation CPI and their role in patients with PD-L1 TPS <1% and distinguishing local progression versus pseudoprogression.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 1","pages":"LMT23"},"PeriodicalIF":2.8,"publicationDate":"2020-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Convex endobronchial ultrasound: same coin, two faces. Challenging biopsy and staging for non-small-cell lung cancer. 支气管内凸超声:同一枚硬币,两面。非小细胞肺癌具有挑战性的活检和分期。
IF 2.8 Q4 RESPIRATORY SYSTEM Pub Date : 2020-01-16 DOI: 10.2217/lmt-2019-0008
Konstantinos Sapalidis, Konstantinos Romanidis, Panagoula Oikonomou, Paul Zarogoulidis, Athanasios Katsaounis, Aikaterini Amaniti, Nikolaos Michalopoulos, Charilaos Koulouris, Kosmas Tsakiridis, Dimitrios Giannakidis, Isaak Kesisoglou, Aris Ioannidis, Iason Nikolaos-Katsios, Anastasios Vagionas, Wolfgang Hohenforst-Schmidt, Haidong Huang, Chong Bai, Alexandru Marian Goganau, Christoforos Kosmidis

Lung cancer is still diagnosed at a late stage due to lack of early disease symptoms. Despite the development of new diagnostic endoscopic tools, such as radial/convex endobronchial ultrasounds (EBUS) and electromagnetic navigation, most patients are still diagnosed at advanced stage disease. Most of the patients refer to their doctor only if they cough blood or their cough changes character. There are challenging cases in the diagnosis and staging of a patient, such as the one that we will present. We present a case of lung cancer that was diagnosed through a biopsy from the main lesion, with access from the esophagus, through transbronchial needle aspiration with EBUS, under general anesthesia and intubation. Staging with transbronchial needle aspiration with EBUS was also performed at the same session.

由于缺乏早期疾病症状,肺癌的诊断仍处于晚期。尽管有了新的内镜诊断工具,如径向/凸支气管超声(EBUS)和电磁导航,但大多数患者仍在晚期诊断。大多数患者只有在咳嗽带血或咳嗽改变特征时才会去看医生。在病人的诊断和分期中有一些具有挑战性的病例,比如我们将要介绍的这个病例。我们报告了一个肺癌病例,在全身麻醉和插管下,通过主要病变的活检诊断,从食道进入,通过经支气管穿刺EBUS穿刺。在同一会议上也进行了经支气管针抽吸EBUS的分期。
{"title":"Convex endobronchial ultrasound: same coin, two faces. Challenging biopsy and staging for non-small-cell lung cancer.","authors":"Konstantinos Sapalidis,&nbsp;Konstantinos Romanidis,&nbsp;Panagoula Oikonomou,&nbsp;Paul Zarogoulidis,&nbsp;Athanasios Katsaounis,&nbsp;Aikaterini Amaniti,&nbsp;Nikolaos Michalopoulos,&nbsp;Charilaos Koulouris,&nbsp;Kosmas Tsakiridis,&nbsp;Dimitrios Giannakidis,&nbsp;Isaak Kesisoglou,&nbsp;Aris Ioannidis,&nbsp;Iason Nikolaos-Katsios,&nbsp;Anastasios Vagionas,&nbsp;Wolfgang Hohenforst-Schmidt,&nbsp;Haidong Huang,&nbsp;Chong Bai,&nbsp;Alexandru Marian Goganau,&nbsp;Christoforos Kosmidis","doi":"10.2217/lmt-2019-0008","DOIUrl":"https://doi.org/10.2217/lmt-2019-0008","url":null,"abstract":"<p><p>Lung cancer is still diagnosed at a late stage due to lack of early disease symptoms. Despite the development of new diagnostic endoscopic tools, such as radial/convex endobronchial ultrasounds (EBUS) and electromagnetic navigation, most patients are still diagnosed at advanced stage disease. Most of the patients refer to their doctor only if they cough blood or their cough changes character. There are challenging cases in the diagnosis and staging of a patient, such as the one that we will present. We present a case of lung cancer that was diagnosed through a biopsy from the main lesion, with access from the esophagus, through transbronchial needle aspiration with EBUS, under general anesthesia and intubation. Staging with transbronchial needle aspiration with EBUS was also performed at the same session.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"8 4","pages":"LMT20"},"PeriodicalIF":2.8,"publicationDate":"2020-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions? 免疫检查点抑制剂在非小细胞肺癌中的再挑战:不同的情况有不同的解决方案?
IF 2.8 Q4 RESPIRATORY SYSTEM Pub Date : 2020-01-16 DOI: 10.2217/lmt-2019-0012
Giulio Metro, Diego Signorelli
{"title":"Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?","authors":"Giulio Metro, Diego Signorelli","doi":"10.2217/lmt-2019-0012","DOIUrl":"10.2217/lmt-2019-0012","url":null,"abstract":"","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"8 4","pages":"LMT18"},"PeriodicalIF":2.8,"publicationDate":"2020-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/8e/lmt-08-18.PMC6978724.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhaled chemotherapy adverse effects: mechanisms and protection methods. 吸入化疗不良反应:机制及保护方法。
IF 2.8 Q4 RESPIRATORY SYSTEM Pub Date : 2020-01-16 DOI: 10.2217/lmt-2019-0007
Chrysanthi Sardeli, Paul Zarogoulidis, Christoforos Kosmidis, Aikaterini Amaniti, Athanasios Katsaounis, Dimitrios Giannakidis, Charilaos Koulouris, Wolfgang Hohenforst-Schmidt, Haidong Huang, Chong Bai, Nikolaos Michalopoulos, Kosmas Tsakiridis, Konstantinos Romanidis, Panagoula Oikonomou, Konstantina Mponiou, Anastasios Vagionas, Alexandru Marian Goganau, Isaak Kesisoglou, Konstantinos Sapalidis

Lung cancer is still diagnosed at a late stage due to a lack of symptoms. Although there are novel therapies, many patients are still treated with chemotherapy. In an effort to reduce adverse effects associated with chemotherapy, inhaled administration of platinum analogs has been investigated. Inhaled administration is used as a local route in order to reduce the systemic adverse effects; however, this treatment modality has its own adverse effects. In this mini review, we present drugs that were administered as nebulized droplets or dry powder aerosols for non-small-cell lung cancer. We present the adverse effects and methods to overcome them.

由于缺乏症状,肺癌的诊断仍处于晚期。虽然有新的治疗方法,但许多患者仍然接受化疗。为了减少与化疗相关的不良反应,研究人员对吸入铂类似物进行了研究。吸入给药作为局部途径,以减少全身不良反应;然而,这种治疗方式有其自身的副作用。在这篇迷你综述中,我们介绍了用于治疗非小细胞肺癌的雾化液滴或干粉气溶胶的药物。我们提出了不良影响和克服它们的方法。
{"title":"Inhaled chemotherapy adverse effects: mechanisms and protection methods.","authors":"Chrysanthi Sardeli,&nbsp;Paul Zarogoulidis,&nbsp;Christoforos Kosmidis,&nbsp;Aikaterini Amaniti,&nbsp;Athanasios Katsaounis,&nbsp;Dimitrios Giannakidis,&nbsp;Charilaos Koulouris,&nbsp;Wolfgang Hohenforst-Schmidt,&nbsp;Haidong Huang,&nbsp;Chong Bai,&nbsp;Nikolaos Michalopoulos,&nbsp;Kosmas Tsakiridis,&nbsp;Konstantinos Romanidis,&nbsp;Panagoula Oikonomou,&nbsp;Konstantina Mponiou,&nbsp;Anastasios Vagionas,&nbsp;Alexandru Marian Goganau,&nbsp;Isaak Kesisoglou,&nbsp;Konstantinos Sapalidis","doi":"10.2217/lmt-2019-0007","DOIUrl":"https://doi.org/10.2217/lmt-2019-0007","url":null,"abstract":"<p><p>Lung cancer is still diagnosed at a late stage due to a lack of symptoms. Although there are novel therapies, many patients are still treated with chemotherapy. In an effort to reduce adverse effects associated with chemotherapy, inhaled administration of platinum analogs has been investigated. Inhaled administration is used as a local route in order to reduce the systemic adverse effects; however, this treatment modality has its own adverse effects. In this mini review, we present drugs that were administered as nebulized droplets or dry powder aerosols for non-small-cell lung cancer. We present the adverse effects and methods to overcome them.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"8 4","pages":"LMT19"},"PeriodicalIF":2.8,"publicationDate":"2020-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Can tumor mutational burden determine the most effective treatment for lung cancer patients? 肿瘤突变负担能否决定肺癌患者最有效的治疗方法?
IF 2.8 Q4 RESPIRATORY SYSTEM Pub Date : 2020-01-14 DOI: 10.2217/lmt-2019-0013
Shixiang Wang, Zaoke He, Xuan Wang, Huimin Li, Tao Wu, Xiaoqin Sun, Kai Wu, Xue-Song Liu
Graphical abstract
{"title":"Can tumor mutational burden determine the most effective treatment for lung cancer patients?","authors":"Shixiang Wang,&nbsp;Zaoke He,&nbsp;Xuan Wang,&nbsp;Huimin Li,&nbsp;Tao Wu,&nbsp;Xiaoqin Sun,&nbsp;Kai Wu,&nbsp;Xue-Song Liu","doi":"10.2217/lmt-2019-0013","DOIUrl":"https://doi.org/10.2217/lmt-2019-0013","url":null,"abstract":"Graphical abstract","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"8 4","pages":"LMT21"},"PeriodicalIF":2.8,"publicationDate":"2020-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Identifying successful biomarkers for patients with non-small-cell lung cancer 非小细胞肺癌癌症患者的成功生物标志物鉴定
IF 2.8 Q4 RESPIRATORY SYSTEM Pub Date : 2019-11-14 DOI: 10.2217/lmt-2019-0009
A. Friedlaender, J. Bauml, G. Banna, A. Addeo
Alex Friedlaender1, Joshua Bauml2, Giuseppe Luigi Banna3 & Alfredo Addeo*,1 1Department of Oncology, University Hospital of Geneva (HUG), 12052, Switzerland 2Abramson Cancer Center, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA 191043, USA 3Oncology Department, United Lincolnshire Hospital Trust, Lincoln, LN2 5QY, UK *Author for correspondence: Alfredo.Addeo@hcuge.ch
Alex Friedlaender1、Joshua Bauml2、Giuseppe Luigi Banna3和Alfredo Addeo*,1日内瓦大学医院肿瘤科,12052,瑞士2宾夕法尼亚大学高级医学佩雷尔曼中心癌症中心,宾夕法尼亚州费城,美国3林肯郡联合医院信托基金会肿瘤科,林肯,LN2 5QY,英国*通信作者:Alfredo.Addeo@hcuge.ch
{"title":"Identifying successful biomarkers for patients with non-small-cell lung cancer","authors":"A. Friedlaender, J. Bauml, G. Banna, A. Addeo","doi":"10.2217/lmt-2019-0009","DOIUrl":"https://doi.org/10.2217/lmt-2019-0009","url":null,"abstract":"Alex Friedlaender1, Joshua Bauml2, Giuseppe Luigi Banna3 & Alfredo Addeo*,1 1Department of Oncology, University Hospital of Geneva (HUG), 12052, Switzerland 2Abramson Cancer Center, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA 191043, USA 3Oncology Department, United Lincolnshire Hospital Trust, Lincoln, LN2 5QY, UK *Author for correspondence: Alfredo.Addeo@hcuge.ch","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2019-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44651007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods 非小细胞肺癌的活检和再活检:当前和未来的方法
IF 2.8 Q4 RESPIRATORY SYSTEM Pub Date : 2019-10-17 DOI: 10.2217/lmt-2019-0006
P. Zarogoulidis, C. Kosmidis, V. Fyntanidou, Z. Aidoni, K. Tsakiridis, Charilaos Koulouris, N. Michalopoulos, Anastasios Barmpas, Hai-dong Huang, C. Bai, W. Hohenforst-Schmidt, K. Sapalidis
Paul Zarogoulidis*,1, Christoforos Kosmidis1, Varvara Fyntanidou2, Zoi Aidoni1, Kosmas Tsakiridis3, Charilaos Koulouris1, Nikolaos Michalopoulos1, Anastasios Barmpas1, Haidong Huang4, Chong Bai4, Wolfgang Hohenforst-Schmidt5 & Konstantinos Sapalidis1 1Third Department of Surgery, ‘AHEPA’ University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece 2Anesthesiology Department, ‘AHEPA’ University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece 3Thoracic Surgery Department, ‘Interbalkan’ European Medical Center, Thessaloniki, Greece 4Department of Respiratory & Critical Care Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, China 5Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, ‘Hof’ Clinics, University of Erlangen, Hof, Germany *Author for correspondence: pzarog@hotmail.com
Paul Zarogoulidis*,1,Christoforos Kosmidi1,Varvara Fyntanidou2,Zoi Aidoni1,Kosmas Tsakiridi3,Charilaos Koulouris1,Nikolaos Michalopoulos1,Anastasios Barmpas1,Haidong Huang 4,Chong Bai4,Wolfgang Hohenforst-Schmidt5&Konstantinos Sapalidis1第三外科,AHEPA大学医院,塞萨洛尼基亚里士多德大学医学院,希腊2希腊塞萨洛尼基亚里士多德大学“AHEPA”大学医院骨科,希腊塞萨洛尼卡医学院,希腊塞萨洛尼基Interbalkan欧洲医学中心,希腊4第二军医大学长海医院呼吸与危重症医学部,中国上海5萨纳诊所集团,德国霍夫埃尔兰根大学霍夫诊所心脏病学/肺病/重症监护/肾病科*通信作者:pzarog@hotmail.com
{"title":"Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods","authors":"P. Zarogoulidis, C. Kosmidis, V. Fyntanidou, Z. Aidoni, K. Tsakiridis, Charilaos Koulouris, N. Michalopoulos, Anastasios Barmpas, Hai-dong Huang, C. Bai, W. Hohenforst-Schmidt, K. Sapalidis","doi":"10.2217/lmt-2019-0006","DOIUrl":"https://doi.org/10.2217/lmt-2019-0006","url":null,"abstract":"Paul Zarogoulidis*,1, Christoforos Kosmidis1, Varvara Fyntanidou2, Zoi Aidoni1, Kosmas Tsakiridis3, Charilaos Koulouris1, Nikolaos Michalopoulos1, Anastasios Barmpas1, Haidong Huang4, Chong Bai4, Wolfgang Hohenforst-Schmidt5 & Konstantinos Sapalidis1 1Third Department of Surgery, ‘AHEPA’ University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece 2Anesthesiology Department, ‘AHEPA’ University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece 3Thoracic Surgery Department, ‘Interbalkan’ European Medical Center, Thessaloniki, Greece 4Department of Respiratory & Critical Care Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, China 5Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, ‘Hof’ Clinics, University of Erlangen, Hof, Germany *Author for correspondence: pzarog@hotmail.com","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2019-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2019-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43285627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Lung Cancer Management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1